I
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Price:
69.44 USD
-1.28%
Market Closed
Updated:
May 3, 2024
Intra-Cellular Therapies Inc
Operating Income
|
Intra-Cellular Therapies Inc
Operating Income Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
I
|
Intra-Cellular Therapies Inc
NASDAQ:ITCI
|
Operating Income
-$159.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-20%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Intra-Cellular Therapies Inc's Operating Income?
Operating Income
-159.4m
USD
-159.4m
USD
Based on the financial report for Dec 31, 2023, Intra-Cellular Therapies Inc's Operating Income amounts to -159.4m USD.
What is Intra-Cellular Therapies Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-20%
-20%
Over the last year, the Operating Income growth was 40%. The average annual Operating Income growth rates for Intra-Cellular Therapies Inc have been 12% over the past three years , and -20% over the past ten years .
You don't have any saved screeners yet
